Using Harmony analysis software (PerkinElmer Co., Ltd.), the level of lysosomal trafficking was expressed as the number of dots per cell and the dot signal intensity. BMC Cancer. The multi-center, open-label, two-cohort, two-part, phase 2 study will evaluate the safety and efficacy of patritumab deruxtecan in patients with advanced or metastatic colorectal cancer who are resistant, refractory, or intolerant to at least two prior approved systemic therapies. After cell binding, HER3-DXd is translocated to the lysosome, with data showing that this occurs in a time- and concentration-dependent manner in all the HER3-mutant and HER3WT cells tested but not in HER3EV cells. Patritumab deruxtecan is currently being evaluated as both a monotherapy and in combination with other anticancer therapies. Secondary objectives of the study include the assessment of antitumor activity (evaluated by assessing duration of response (DoR), investigator-assessed ORR, disease control rate (DCR), time to response (TTR), progression-free survival (PFS) and overall survival (OS)), safety and tolerability, level of HER3 protein expression in tumor tissue and its relationship with efficacy, pharmacokinetics and immunogenicity. Similarly, early data from a phase 1 trial in patients with metastatic/unresectable EGFR tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutated NSCLC showed HER3-DXd had a manageable safety profile and clinically meaningful antitumor activity (NCT0326049) [19]. 2020. Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. 1998;29(8):771-777. Future studies analyzing HER2 expression in fresh biopsy and circulating tumor DNA will help shed light on the relationship between HER2 expression and T-DXd efficacy and the bystander antitumor effect, possibly leading to improved patient selection. on. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Groups 2025 Vision to become a Global Pharma Innovator with Competitive Advantage in Oncology, Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. This feature is particularly desirable when targeting tumors with heterogenous expression of the targeted antigen, as is the case for HER2-positive GC.
Patritumab Deruxtecan Granted U.S. FDA Breakthrough Therapy Designation [1] Van Cutsem E, et al. Individual cell growth inhibition activity of HER3-DXd, patritumab, IgG-ADC, and payload against MDA-MB-231 cells transduced with lentiviral vectors encoding flag-tagged HER3 wild-type or HER3 mutations. PRs were observed in 42.9% of patients and 50.0% of patients had a BOR of SD. Patritumab deruxtecan is an investigational medicine that has not been approved for any indication in any country. The FDA has granted a breakthrough therapy designation to patritumab deruxtecan for the treatment of patients with metastatic or locally advanced EGFR -mutated non-small cell lung cancer (NSCLC . A t-test was performed using SAS System Release 9.2 (SAS Institute, Inc, Cary, NC) to compare whether the treatment groups (HER3-DXd, patritumab, and DXd) were different from the control group. Patritumab deruxtecan (HER3-DXd) is one of three lead DXd ADCs in the oncology pipeline of Daiichi Sankyo. The authors recommend that the flowchart shown in Fig. The Patritumab deruxtecan is a type of medication known as an Antibody Drug Conjugate. Shiose Y, Ochi Y, Kuga H, Yamashita F, Hashida M. Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. About Breast Cancer and Non-Small Cell Lung Cancer, Breast cancer is the most common cancer and is one of the leading causes of cancer-related deaths worldwide.5 More than two million cases of breast cancer were diagnosed in 2020 with nearly 685,000 deaths globally.5 The five-year survival rate of advanced breast cancer is 30% in the U.S.1, Lung cancer is the second most common cancer and the leading cause of cancer-related deaths worldwide.6 More than 2.2 million cases of lung cancer were diagnosed in 2020, resulting in nearly 1.8 million deaths globally.6 NSCLC accounts for about 84% of all lung cancers.7 About half of patients with NSCLC are diagnosed at an advanced stage and they often have a poor prognosis with worsening outcomes after each line of subsequent therapy.8,9,10 The five-year survival rate of advanced lung cancer is 7% in the U.S.2. FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast cancer. Atlanta: American Cancer Society, 2020. These results indicate that the management of nausea is important during T-DXd treatment. Although ADCs are an innovative class of anticancer drugs and are expected to improve the outcome in a subset of patients, several concerns should be addressed. patritumab deruxtecan Treatment of lung cancer MHRA-100385-PIP01-21 datopotamab deruxtecan Treatment of breast cancer MHRA-100384-PIP01-21 MHRA-100311-PIP01-21 Cetrelimab Treatment of urothelial carcinoma MHRA-100326-PIP01-21 GEMCITABINE HYDROCHLORIDE Not available at present On the basis of the promising efficacy, phase II study exploring the safety and efficacy of patritumab deruxtecan as a single agent in EGFR-mutated NSCLC after progression on EGFR-TKIs has been initiated (NCT04619004). Representative images for trafficking of pHrodo-labeled HER3-DXd in MDA-MB-231 cells transduced with HER3WT, HER3 mutations, and HER3EV in the absence (A) or presence (B) of HER2 overexpression. Mit Enhertu werden Erwachsene mit einem speziellen Brustkrebs behandelt, dem soge-nannten HER2-positiven Brustkrebs. The overexpression of HER2 had little or no impact on the cell-surface binding of HER3-DXd to the various transduced cells (Fig 1), under the levels of HER2 overexpression as shown in S3 Fig. One cohort will include patients with HER3 high expression (IHC 3+ or 2+), and the second cohort will include patients with HER3 low/HER3 negative expression (IHC 1+ or 0). 2020. EGFR is the most common oncogenic mutation found in NSCLC, and EGFR exon 19 deletion or L858R point mutation in exon 21 is associated with response to EGFR tyrosine kinase inhibitors (EGFR-TKI; ref. Cardiotoxicity is known to be a serious side effect in patients with breast cancer who are treated with HER2-targeted therapies including trastuzumab [3335]; however, the incidence of cardiotoxicity in patients with gastric or breast cancer treated with T-DXd appears to be low and was not observed in the DESTINY-Gastric01 trial [9, 31]. PLoS ONE 17(5): Before The primary objective of this part of the trial was to assess the safety and tolerability of patritumab deruxtecan and determine the recommended dose for expansion (RDE). [10] Jeong JH, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Antiemesis Version 2.2020. In the setting of emergent resistance to EGFR-TKIs, MET amplification is the most common bypass pathway in patients with EGFR-mutant NSCLC, representing MET as an attractive target for ADC development. These data suggest that the cell growth-inhibition activity of HER3-DXd is dependent on the payload released within the cells, after the binding to cell-surface HER3 and the trafficking to lysosome. As previously mentioned, nausea and vomiting are commonly reported with T-DXd treatment (nausea any grade, 6378%; nausea grade3, 58%; vomiting any grade, 2646%; vomiting grade3, 04%) [25, 40], which highlights a need for effective management. The amount of HER3-DXd bound to the surface of each of the HER3 mutant cells was similar to the amount bound to the HER3WT cells at all the concentrations tested, with binding saturation being reached at around 10 nM. S.M. Median progression-free survival (PFS) was 7.4 months (95% CI: 4.7-8.4) and median overall survival (OS) was 14.6 months (95% CI: 11.3-19.5). National Library of Medicine A FLAG-negative cell line was used as a negative control. The first part of the study will include two cohorts of patients with varying levels of HER3 expression.
Patritumab Deruxtecan in patients with Non-Small Cell Lung Cancer Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC 162O - Primary analysis from DS8201-A-U105: A 2-part, open label, phase 1b trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer Final gross price and currency may vary according to local VAT and billing address. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Cell viability was calculated as the luminescence intensity of the test well divided by the mean luminescence intensity of untreated wells multiplied by 100. The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to . Pooled safety was analyzed for all patients (n=182) enrolled in the trial.
Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies. Trafficking (trafficking index) of pHrodo-labeled HER3-DXd in MDA-MB-231 cells transduced with HER3WT, HER3 mutations, or HER3EV in the absence (A) or presence (B) of HER2 overexpression. TEAEs that led to dose reductions were reported in 16% and 32% of patients in the phase 1 and phase 2 trials, respectively. Genomic alterations of ERBB receptors in cancer: clinical implications. HER3-DXd is being evaluated in clinical trials for the treatment of breast cancer and NSCLC, cancers that commonly express HER3 [17]. Development of linker chemistry or inhibition of drug efflux would hold a key to combat resistance mechanisms, which need further investigation. PLOS ONE promises fair, rigorous peer review, Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. Macrophages expressed cathepsin B, one of the enzymes capable of linker cleavage of T-DXd [24, 44]. About Daiichi Sankyo Cancer Enterprise Seven clinical trials are in progress to evaluate HER3-DXd for the treatment of patients with breast cancer or NSCLC [17]; these are tumors that are known to overexpress HER3 and in which HER3 mutations have been reported [1, 3, 4]. Most ECD mutations are at critical locations, such as the dimerization site or the border between two subdomains, possibly causing a shift toward the active confirmation of HER3 [11, 13]. Taken together, these data point to a need for more rigorous and sensitive HER2 testing methods to identify HER2-low patients who might benefit from T-DXd treatment. T-DXd showed a non-linear pharmacokinetic profile and the half-life of T-DXd increased at higher doses; drug exposure increased more than the dose ratio at doses above 3.2 mg/kg. Representative: Sunao Manabe, Representative Director, President and CEO
Vice President, Corporate Communications Department
For more information, visit ClinicalTrials.gov. Treatment management for patients who experience T-DXd-related ILD and other adverse events (AEs) is discussed, and recommendations are provided based on the authors experience. Images represent cells 6 hours after addition of 1 nM pHrodo-labeled HER3-DXd and were taken with a 63 water immersion objective lens.
PDF Strategic Collaboration Trastuzumab Deruxtecan DS-8201 - AstraZeneca This potency indicates that DXd would be an ideal payload candidate for ADC. Abbreviations: ADC = antibody drug conjugate, EV = empty vector, HER = human epidermal growth factor receptor, IgG = immunoglobulin G, SD = standard deviation, WT = wild type. Median PFS was 5.5 months (95% CI: 3.9-6.8) and the median OS was 14.6 months (95% CI: 11.2-17.2). This indicates unique challenges for the development of anti-HER2 treatment for HER2-positive GC.
Patritumab Deruxtecan Continues to Show Promising Clinical Activity in In addition, 2% to 13% of patients showed HER2 amplification at the time of acquired resistance to EGFR-TKIs, revealing HER-2directed ADCs as an appealing treatment option. The cell-surface HER2 expression level was assessed by flow cytometry. In NSCLC, increasing numbers of ADCs have been under development targeting various molecules. Promoting efficient internalization of ADCs through target modification can be a supplemental approach to broaden the benefit of ADCs. Research shows that HER3 mutations are observed in many solid tumors, although they occur at a relatively low frequency; data suggest incidences of between 1% and 11% depending on the tumor type [3, 9, 11]. Most ILD events were low-grade with three (1.6%) grade 1 and five (2.7%) grade 2 events; three grade 3 (1.6%) and one grade 5 (death) event occurred (0.5%). Designed using Daiichi Sankyo's proprietary DXd ADC technology, patritumab deruxtecan is comprised of a fully human anti-HER3 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor. [2] NCCN Clinical Practice Guidelines in Oncology (Colon Cancer). E Baba reports grants and personal fees from Taiho, Chugai, Astellas, Merck Biopharma, Daiichi Sankyo, Ono, Kyowa-Kirin, Eisai, Eli Lilly, MSD, Sanofi, Yakult, and Takeda. It is hypothesized that the T355I mutation shifts HER3 to an active conformation, promoting dimerization with the HER family receptors EGFR and HER4. T-DXd was created as a novel ADC that could overcome these challenges using advanced ADC technology. PRs were observed in 22.6% of patients and 56.6% of patients had a BOR of SD. Median PFS was 10.8 months (95% CI: 2.8-16.0). Certain HER3 mutants have demonstrated oncogenic driver activity in the absence or presence of HER2, and some can confer resistance to EGFR and HER2 directed therapies [9, 11, 13]. [6] Rajkumar T, et al. broad scope, and wide readership a perfect fit for your research every time. It is hoped that the results from these ongoing clinical trials will help pave the way for T-DXd in earlier lines of treatment as a single agent or in combination with other agents. In summary, findings from this study demonstrate that efficient payload delivery via ADC-mediated internalization can be achieved across different clinically observed HER3 mutations. Cell Therapy Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan, Affiliation: This study included a dose escalation and expansion cohort, most of the patients being previously treated with osimertinib (72/81, 89%). Along with efforts to advance the treatment of HER2-postive GC, it is important to develop more effective T-DXd treatment strategies for patients with HER2-low tumors, as these patients are not included in the trials evaluating T-DXd for HER2-positive GC. In December 2021, patritumab deruxtecan was granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic or. TEAEs that occurred in20% of patients in the DESTINY-Gastric01 phase 2 trial are shown in Table Table1.1. The 2-part phase 3 human epidermal growth factor 3 (HER3)-Lung study of patritumab for treatment of patients with non-small cell lung cancer (NSCLC) will not proceed into the second part . With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an "Innovative Global Healthcare Company Contributing to the Sustainable Development of Society." Of note, in the DESTINY-Gastric01 trial, patients with GC were excluded if they had or were suspected to have interstitial lung disease/pneumonitis, or if they had a history of noninfectious interstitial lung disease/pneumonitis that had been treated with steroids. Janjigian YY, Viglianti N, Liu F, Mendoza-Naranjo A, Croydon L. A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03). (Adapted from Mishra R, Hankler AB, Garrett JT. Binding triggers receptor-mediated internalization and, once internalized, the payload takes action on the cell. Acta Pharm Sin B. Patritumab deruxtecan is a potential first-in-class HER3-directed antibody-drug conjugate, which signaled efficacy in a phase 1 dose-escalation and dose-expansion study (U31402-A-U102; NCT03260491), which primarily assessed the safety and tolerability of patritumab deruxtecan in patients with EGFR -mutant NSCLC with resistance to EGFR TKIs. As of data cut-off of January 28, 2022, five patients (10.6%) remained on treatment with patritumab deruxtecan. Five patients (10.6%) had confirmed treatment-related ILD as determined by an independent adjudication committee. Given the prevalence of HER2-postive GC, therapies targeting HER2 have been evaluated in this patient population. Fluorescence emission images were then collected at 30-minute intervals for up to 12 hours. Intriguingly, EGFR-directed ADCs have also been developed and tested in EGFR-mutated NSCLC progressed on standard treatment. S3 Table. Trastuzumab deruxtecan is distinguished by a unique biochemical structure with a novel cytotoxic payload, deruxtecana highly potent, topoisomerase I inhibitor. Translational Science Department I, Daiichi Sankyo Co., Ltd., Tokyo, Japan, Affiliation: Finally, future perspectives for T-DXd treatment in clinical practice, including therapeutic evaluations in ongoing clinical trials and author opinions on important future research, are discussed. Bispecific antibodies targeting EGFR and c-MET simultaneously, such as amivantamab, can be useful irrespective of acquired resistance mechanisms, occupying a unique position in the treatment landscape of EGFR-TKI resistance. [25]. 2020;20(1):260.11 Scharpenseel H, et al. The NCCN guidelines recommend G-CSF treatment for prophylaxis of febrile neutropenia based on patient risk factors [50]. Taken together, these findings identify HER3 as an attractive target for cancer therapy [1, 6]. The cells were treated with the pHrodo-labelled HER3-DXd, 100 nM LysoTracker Green DND-26, and 100 ng/mL Hoechst 33342 (both Thermo Fisher Scientific Inc). In general, the authors agree that these recommendations are appropriate. The MFI of an unstained sample was used as background and subtracted from the result for each stained sample. The global, open-label, three-part phase 1/2 trial is evaluating the safety and efficacy of patritumab deruxtecan in patients with HER3 expressing advanced/unresectable metastatic breast cancer who are refractory or intolerant to standard treatment, or for whom no standard treatment is available. It is comprised of 3 components: an anti-HER3 monoclonal antibody, patritumab, that is linked (connected) to a chemotherapy (topoisomerase I inhibitor0 payload, and an exatecan derivative, through a tetrapeptide-based cleavable linker. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Discover a faster, simpler path to publishing in a high-quality journal. Adverse events occurring in at least 20% of the patients treated with trastuzumab deruxtecan. deruxtecan is distinguished by a unique biochemical structure with a novel cytotoxic payload, deruxtecana highly potent, topoisomerase I inhibitor. The effects of 10 nM of HER3-DXd, patritumab, or DXd payload on the growth of HER3 transfectants after 6 days of incubation were assessed and statistically compared with the control. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. The mechanism of action of T-DXd is bystander antitumor effect, which occurs when the cytotoxic payload is released in the tumor cells, diffuses across membranes (due to the high membrane permeability of the payload), and then enters and kills neighboring tumor cells (Fig. These analyses may elucidate the molecular mechanisms of primary and acquired T-DXd resistance in GC. It is designed to target and help deliver chemotherapy to cancer cells that express HER3 on the surface of tumor cells. Patritumab deruxtecan (U3-1402) is one of three lead DXd antibody drug conjugates (ADC) in the oncology pipeline of Daiichi Sankyo. The occurrence and functional relevance of HER3 mutations are of increasing interest to the scientific community given the importance of HER3 in HER2 signaling and the development of acquired therapeutic resistance [11]. Fluorescence emission images were then collected at 30-minute intervals for up to 12 hours. (patritumab, U3-1287) di-rected against the extracellular domain of HER3, covalently Yamaguchi K, Bang Y, Iwasa S, Sugimoto N, Ryu M, Sakai D, et al. 2021; 10.3322/caac.21660.6 World Health Organization. An objective response rate (ORR), as assessed by blinded central review, was 39% (CI 95%; 26-52%) in 57 evaluable patients treated with patritumab deruxtecan (5.6 mg/kg). IgG-ADC is the negative control. HER3-DXd did not bind to the surface of HER3EV cells.
Patritumab deruxtecan (HER3-DXd), a novel HER3 directed - PubMed will also be available for a limited time.
New Biomarker Analyses from Patritumab Deruxtecan Phase 1 - BioSpace FOIA Call your doctor at once if you have: chest tightness, wheezing, cough, new or worsening shortness of breath; pounding heartbeats or fluttering in your chest; fever, tiredness, dizziness; swelling in your lower legs, sudden weight gain; a light-headed feeling, like you might pass out; 1). One confirmed complete response and 21 partial responses were observed. National Center for Advancing Translational Sciences (NCATS), 6701 Democracy Boulevard, Bethesda MD 20892-4874 301-594-8966 Lung Fact Sheet. Cells were harvested as cell suspension, and then incubated on ice for 1 hour with 0.1, 1, 10, and 100 nM HER3-DXd in stain buffer. Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose "to contribute to the enrichment of quality of life around the world." The tumor expression level of HER2 has been shown to have an impact on the efficacy of T-DXd. Moasser MM. (2020) Massachusetts Medical Society. The DESTINY-Gastric01, for patients with HER2-positive gastric or GEJ cancer who were previously treated with2 lines of therapy, including trastuzumab, met its primary endpoint of significantly improved objective response rate for T-DXd versus physicians choice (PC) treatment (51% versus 14%, respectively; P<0.001) [25].